APR 27, 2017 02:36 PM PDT

Technique Prevents Graft-Versus-Host Disease

WRITTEN BY: Xuan Pham

Bone marrow transplants are often considered to be the last resort treatment, because the procedure could have the nearly same chance of saving a patient as it does harming the patient. But now, scientists at the City of Hope say they have found a way to make the procedure safer for patients.

For patients with leukemia or lymphoma, a stem cell or bone marrow transplant is considered the only curative therapy. The procedure replaces a patient’s diseased blood stem cells with healthy ones from a matched donor. But in some cases, the donor’s cells can attack the recipient’s health tissues, and can cause tremendous multiple organ complications. This attack is known as graft-versus-host disease (GVHD).

"Currently, immunosuppressive drugs have been used to prevent GVHD, but immune-suppressants also subdue the anti-cancer effects of the donor T cells, potentially resulting in cancer relapse, in addition to other side effects such as an increased risk of infection," said Defu Zeng, who led the international collaboration at the City of Hope. "Therefore, prevention of GVHD while preserving anti-cancer effects remains the 'holy grail' of allogenic HCT [hematopoietic cell transplantation]." Of note, allogenic HTC refers to using stem cells derived from a donor.

The team report that one way to prevent GVHD is to temporarily deplete a specific type of of donor T cells, called CD4+, following the infusion of stem cells. In the absence of low CD4+ cells, another type of T cells, called CD8+, seems to be more focused on destroying tumor cells rather than the healthy cells. This has the effect of boosting graft-versus-leukemia, while preventing graft-versus-host disease.

"If successfully translated into clinical application, this regimen may represent one of the novel approaches that allow strong GVL effects without causing GVHD," said Zeng. "This kind of regimen has the potential to promote wide-spread application of allogenic HCT as a curative therapy for hematological malignancies."

So far the study has been limited to mouse models. Next, Zeng and colleagues plan to apply this method in human clinical trials.

Additional sources: City of Hope

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 12, 2018
Cell & Molecular Biology
JUN 12, 2018
Loss of Brain Lesions may Indicate Worsening MS
New research could help doctors determine how severe a case of multiple sclerosis will become....
JUN 12, 2018
Immunology
JUN 12, 2018
Auto-antibody Detection for Rheumatoid Arthritis Patients
No case of rheumatoid arthritis (RA), an autoimmune disease, is the same. Now, researchers want RA diagnostic approaches to match its pathological diversit...
JUN 18, 2018
Immunology
JUN 18, 2018
Detecting and Diagnosing Rheumatoid Arthritis Before it Begins
Unique gene signatures and tiny changes in the immune system that occur in the earliest stages of rheumatoid arthritis, an autoimmune disease, could soon b...
JUN 27, 2018
Clinical & Molecular DX
JUN 27, 2018
Are High-Strength MRIs Releasing Mercury from Dental Fillings?
A super strong MRI approved by the U.S. Food and Drug Administration (FDA) may be releasing dangerous amounts of mercury from tooth fillings. From Akdeniz...
JUL 11, 2018
Clinical & Molecular DX
JUL 11, 2018
Certain tests better flag fetuses with brain disorder risk
Fetuses with a specific, rare chromosomal aberration have a 20 percent risk of developmental or other brain disorder, new research shows. The work could le...
OCT 21, 2018
Technology
OCT 21, 2018
Stress-free Sensor Technology Measures an Unborn Heartbeat
Monitoring the heartbeat of the unborn is known to be stressful for expectant mothers. However, recent research at the University of Sussex may ease this p...
Loading Comments...